Abstract
Background A growing body of evidence suggests that neuroinflammation contributes actively to pathophysiology of Alzheimer’s disease (AD) and promotes AD progression. The predictive value of neuroinflammatory biomarkers for disease-staging or estimating disease progression is not well understood. In this study, we investigate the diagnostic and prognostic utility of inflammatory biomarkers in combination with conventional AD biomarkers.
Methods We included 258 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) who had CSF biomarkers of β-Amyloid (Aβ), tau, and inflammation. The primary outcome of interest was clinically meaningful cognitive decline (CMCD) as defined by an increase of ≥4 on the Alzheimer’s Disease Assessment Scale Cognitive Subscore 11 (ADAS-11, scores 0-70, higher scores indicate worse cognition). Predictor variables were categorized as demographics (D; age, sex, and education), genetic (APOE4 status (A)), inflammatory biomarkers (I), and classic (C) cerebrospinal fluid (CSF) biomarkers of Aβ and p-tau181. Simultaneous inclusion of eleven CSF inflammatory biomarkers as covariates in logistic regression models was examined to assess improvements in classifying baseline clinical diagnoses (cognitively normal (CN), mild cognitive impairment (MCI), Dementia) and predicting individuals with and without CMCD over one year of follow-up.
Results At 1-year follow up, 27.1% of participants experienced CMCD. Inclusion of inflammatory biomarkers improved baseline classification of CN vs MCI as well as CN vs Dementia for models including D and A variables (DA; both p<0.001). Similarly, when classic CSF biomarkers of AD were included into the model (DAC model), inclusion of inflammatory markers improved classification of CN vs MCI (p<0.01) as well as CN vs Dementia (p<0.001). Addition of inflammatory biomarkers to both DA and DAC models improved predictive performance for CMCD in persons with baseline MCI and Dementia (all p<0.05), but not in the CN group. In addition, the predictive performance of the DAI model was superior to the DAC model in the MCI and Dementia groups (both p<0.05).
Conclusions Addition of CSF inflammatory biomarkers to CSF biomarkers of AD can improve diagnostic accuracy of clinical disease stage at baseline and add incremental value to AD biomarkers for prediction of cognitive decline.
Learning objective □ Identify potential diagnostic and prognostic ability of inflammatory biomarkers to assess Alzheimer’s disease stage and cognitive decline.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by grants from the National Institute of Health (NIA K23 AG063993; AG080635; AG003949) the Alzheimer's Association (SG-24-988292 ISAVRAD), Cure Alzheimer's Fund, and the Leonard and Sylvia Marx Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The revised version includes the correct form of the author's names.
Data Availability
https://adni.loni.usc.edu/ we used ADNI data which is openly available here.
